STANFORD UNIVERSITY

The FDA approved Cobenfy, a new schizophrenia treatment with fewer side effects than current drugs, targeting muscarinic receptors instead of dopamine. Marketed by Bristol Myers Squibb, it will be available at $1,850 a month starting in October, with potential for long-term benefits in negative symptoms like apathy and lack of motivation.

Dr. Florence Comite emphasizes the importance of deep sleep, muscle building, and blood sugar monitoring to stem aging, citing their roles in diabetes prevention and overall health.

OUWB's Women in Medicine Month concluded with a keynote by Oakland University President Ora Hirsch Pescovitz, focusing on career goal-setting and self-reflection. The month featured additional events including a panel discussion, AI presentation by alumnus Flo Doo, and a documentary screening on Black women in medicine.

New graduate students advised to avoid comparisons, seek help, enjoy campus perks, and find a lab 'fit' by assessing collegiality, conflict dynamics, and personal relationships with faculty.

The BMJ report questions Kisunla's safety, citing deaths and financial ties of panel members. FDA initially denied approval due to missing data and safety concerns, later approving it. Lilly acknowledged deaths, hired an outside company for data, but refused to disclose details. Panel members had financial ties to drug companies, raising concerns about bias. Lilly's claims of drug effectiveness were criticized for being misleading.

Donanemab, an Alzheimer’s drug by Eli Lilly, faces scrutiny over excess deaths, missing safety data, questionable efficacy, and financial conflicts among FDA advisory panel members. Despite these concerns, the FDA approved the drug in July 2023, raising questions about the approval process and the drug's true benefits and risks.

FDA-approved Alzheimer’s drug donanemab faces scrutiny over effectiveness, safety, and undisclosed financial conflicts among FDA advisers who recommended its approval.

Chronic pain treatment involves a lengthy trial-and-error process due to individual variability. Advances in biomarkers and AI show promise for personalized pain medicine, potentially revolutionizing treatment matching.

PSC-CM research has advanced heart disease understanding, tissue engineering, and drug discovery. Bibliometric analysis (2007-2024) shows U.S. dominance, with Stanford University and Joseph C. Wu leading. Key research areas include organ-on-a-chip, 3D bio-printing, and cardiac organoids. Challenges in stem-cell-mediated therapies persist.